Brachytherapy

What is it?

Brachytherapy delivers radiation internally. There are 2 main types: low-dose seed implant brachytherapy and high-dose rate brachytherapy (HDR).

Low-dose seed implant brachytherapy
  • Usually recommended to men with lowergrade cancers that are contained within the prostate gland.
  • Between 80 and 100 radioactive seeds, the size of a grain of rice, are implanted directly into the prostate.
  • Each seed releases low-energy level radiation steadily over several months.
HDR
  • Reserved for patients with high-grade cancers.
  • High-dose radiation is received through approximately 15 needles in the prostate, concentrating on the cancerous areas.
What is done?

Low-dose seed implant brachytherapy
  • The seeds are inserted through the skin in the perineum.
  • Procedure is performed under either general or spinal anesthesia and lasts approximately 1 hour.
HDR
  • Under anesthesia, approximately 10–15 needles are inserted through the perineum.
  • These needles are wired to the radiation source that delivers a high radiation dose to the prostate.
  • The needles are then removed.
  • The treatment takes 10–20 minutes.
What to expect?

Low-dose seed implant brachytherapy
  • A catheter may be used for a short time for urine drainage.
HDR
  • Often preceded or followed by a few weeks of external beam radiation.
  • Sometimes HDR treatments are given over a few days and the external beam radiation is not needed.
Side effects and risks
  • Side-effects of brachytherapy are similar to those of external beam radiation.
  • Brachytherapy differs slightly in the following ways:
    • Dominant short-term side-effect is irritation to the bladder and urethra
    • Acute urinary r etention may develop
    • Bowel irritation is relatively uncommon
    • Side effects may last months
Long term side effects
  • Very rare risk of incontinence of urine or chronic urinary obstruction (both less than 5%).
  • Erectile Dysfunction may occur, though many men will be able to achieve an erection with the use of prescription medication.

For more information and support:









Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive